Approach Targets Macrophages in BRCA-Linked Breast Cancer

PARP inhibitors have become an important part of the arsenal for treating cancers caused by BRCA mutations — including breast cancer. Recently, clinical trials have begun looking at the combination of PARP inhibitors and immune checkpoint inhibitors in breast cancer, with the goal of making treatment more effective and longer lasting.